Abstract:One of the cornerstones of rational drug development is the measurement of molecular parameters derived from ligand-receptor interaction, which guides therapeutic windows definition. Over the last decades, radioligand binding has provided valuable contributions in this field as key method for such purposes. However, its limitations spurred the development of more exquisite techniques for determining such parameters. For instance, safety risks related to radioactivity waste, expensive and controlled disposal of radioisotopes, radiotracer separation-dependence for affinity analysis, and one-site mathematical models-based fitting of data make radioligand binding a suboptimal approach in providing measures of actual affinity conformations from ligands and G proteincoupled receptors (GPCR). Current advances on high-throughput screening (HTS) assays have markedly extended the options of sparing sensitive ways for monitoring ligand affinity. The advent of the novel bioluminescent donor NanoLuc luciferase (Nluc), engineered from Oplophorus gracilirostris luciferase, allowed fitting bioluminescence resonance energy transfer (BRET) for monitoring ligand binding. Such novel approach named Nluc-based BRET (NanoBRET) binding assay consists of a real-time homogeneous proximity assay that overcomes radioligand binding limitations but ensures the quality in affinity measurements. Here, we cover the main advantages of NanoBRET protocol and the undesirable drawbacks of radioligand binding as molecular methods that span pharmacological toolbox applied to Drug Discovery. Also, we provide a novel perspective for the application of NanoBRET technology in affinity assays for multiple-state binding mechanisms involving oligomerization and/or functional biased selectivity. This new angle was proposed based on specific biophysical criteria required for the real-time homogeneity assigned to the proximity NanoBRET protocol.

Ligand-Based Competition Binding by Real-Time 19 F NMR in Human Cells

Label-Free Quantification of Molecular Interaction in Live Red Blood Cells by Tracking Nanometer Scale Membrane Fluctuations.

Fluorescence Biomembrane Force Probe: Concurrent Quantitation of Receptor-ligand Kinetics and Binding-induced Intracellular Signaling on a Single Cell

Direct Expression of Fluorinated Proteins in Human Cells for 19F In-Cell NMR Spectroscopy

Label-Free Chemical Nano-Imaging of Intracellular Drug Binding Sites

In‐Cell 19F NMR of Proteins: Recent Progress and Future Opportunities

New Horizons on Molecular Pharmacology Applied to Drug Discovery: When Resonance Overcomes Radioligand Binding

GPCR structural characterization by NMR spectroscopy in solution

Inducible protein expression in stably transfected cells paves the way toward in-cell NMR studies in defined physiological states and 3D tissue cultures.

NMR-Based Methods for Protein Analysis

Conformational Dynamics in GPCR Signaling by NMR

Simultaneous Quantification Of Protein Binding Kinetics In Whole Cells With Surface Plasmon Resonance Imaging And Edge Deformation Tracking

In Situ Drug-Receptor Binding Kinetics in Single Cells: a Quantitative Label-Free Study of Anti-Tumor Drug Resistance

Enhancing Molecular‐Level Biological Monitoring with a Smart Self‐Assembling 19F‐Labeled Probe

Probing the Conformation States of Neurotensin Receptor 1 Variants by NMR Site-Directed Methyl Labeling

Ligand Proton Pseudocontact Shifts Determined from Paramagnetic Relaxation Dispersion in the Limit of NMR Intermediate Exchange.

Structure-based drug design: NMR-based approach for ligand-protein interactions.

Simultaneous detection of intracellular target and off-target binding of small molecule cancer drugs at nanomolar concentrations

Applications of NMR screening techniques to the pharmaceutical target Checkpoint kinase 1

Binding affinity-based intracellular drug detection enabled by a unimolecular cucurbit[7]uril-dye conjugate

Real-Time Biomolecular Binding Detection Using A Sensitive Photonic Crystal Biosensor